On 16 April 2026, the Committee for Veterinary Medicinal Products (‘CVMP’) concluded that no further MRL assessment is necessary and that the substance can be included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 with a ‘No MRL required’ classification [Recombinant equine Chorionic Gonadotropin (reCG): Summary of assessment. (EMA/CVMP/5612/2026-16 April 2026): https://www.ema.europa.eu/en/documents/mrl-summary/recombinant-equine-chorionic-gonadotropin-recg-summary-assessment_en.pdf.].
Recital 7, Regulation (EU) 2026/1806
In forcesince 24 Jul 2026